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Abstract 
Background: High‑mobility group box 1 (HMGB1) was observed to be an important extracellular mediator involved 
in vascular inflammation associated with subarachnoid hemorrhage (SAH). This study is of interest to examine the effi‑
cacy of 4′‑O‑β‑d‑glucosyl‑5‑O‑methylvisamminol (4OGOMV), C22H28O10, on the alternation of cytokines and HMGB1 in 
an animal model.
Methods: A rodent double hemorrhage SAH model was employed. Administration with 4OGOMV was initiated 1 h 
after animals were subjected to SAH. Basilar arteries (BAs) were harvested and cortexes examined for HMGB1 mRNA, 
protein expression (Western blot) and monocyte chemoattractant protein‑1 (MCP‑1) immunostaining. Cerebrospinal 
fluid samples were collected to examine IL‑1β, IL‑6, IL‑8 and MCP‑1 (rt‑PCR).
Results: Morphological findings revealed endothelial cell deformity, intravascular elastic lamina torture, and smooth 
muscle necrosis in the vessels of SAH groups. Correspondently, IL‑1β, IL‑6 and MCP‑1 in the SAH‑only and SAH‑plus 
vehicle groups was also elevated. 4OGOMV dose‑dependently reduced HMGB1 protein expression when compared 
with the SAH groups.(p < 0.01) Likewise, 400 μg/kg 4OGOMV reduced IL‑1β, MCP‑1 and HMGB1 mRNA levels as well 
as MCP‑1(+) monocytes when compared with the SAH groups..
Conclusion: 4OGOMV exerts its neuro‑protective effect partly through the dual effect of inhibiting IL‑6 and MCP‑1 
activation and also reduced HMGB1 protein, mRNA and MCP‑1(+) leukocytes translocation. This study lends credence 
to validating 4OGOMV as able to attenuate pro‑inflammatory cytokine mRNA, late‑onset inflammasome, and cellular 
basis in SAH‑induced vasospasm.
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Background
Subarachnoid hemorrhage (SAH)-induced cerebral vasos-
pasm persists as a major cause of morbidity and mortality 
in patients suffering from aneurysm rupture [1–7]. Owing 
to lack of effective therapies to amend this condition, the 
precise mechanisms of this disease content need further 
investigation. An ongoing body of research summarizes 
two major hypotheses: one is focused on the immedi-
ate role of endothelins/nitric oxide [8] and another on 
SAH-induced oxidative stress and a series of inflamma-
tory reaction in the development and maintenance of 
vasoconstriction [9–16]. As we know in the condition of 
SAH, oxy-hemolysate will culminate a cascade of cellular 
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and molecular events in the subarachnoid space and fur-
ther result in a robust inflammatory response [2, 3]. Even 
if the systemic inflammation has been recognized in the 
pathogenesis of cerebral vasospasm, the putative impor-
tance of intracranial sterile inflammatory activity has not 
been fully emphasized. Till now, various inflammosomes, 
including adhesion molecules, cytokines, leukocytes, 
immunoglobulins, and complements, were observed in 
the pathogenesis of SAH-induced cerebral infarct and 
vasospasm [1, 7, 8, 17–20].
The levels of pro-inflammatory cytokines and adhe-
sion molecule have been found increased in cerebrospi-
nal fluid (CSF) after SAH [10, 15]. However, the benefits 
of inflammation associated with SAH remain unclear. 
High-mobility group box 1 (HMGB1), a ubiquitous 
nuclear protein, is expressed in activated monocytes, 
macrophages, circulating neutrophils, and platelets [13, 
17, 21]. In Wolfson et al’s study, HMGB1 is proved to be 
able to mediate vascular monocyte chemotaxis, neuron 
dendrite outgrowth, and the proinflammatory reaction of 
endothelial cells [16]. The released HMGB1 is late-onset 
to tumor necrosis factor-α (TNF-α) and interleukin-1β 
(IL-1β) kinetically. Park et  al. [22] also demonstrated 
HMGB1, through binding glycation end products 
(RAGE) and toll-like receptor (TLR)-2 and TLR-4 recep-
tors, was able to activate nuclear factor-κB (NF-κB) and 
extracellular-regulated kinase (ERK) 1 and ERK 2. As a 
late mediator, HMGB1 is able to induce the expression 
of vascular cell-adhesion molecule (VCAM), intercellu-
lar adhesion molecule (ICAM), and E-selectin, and lead 
to up-regulating the recruitment of leukocytes [21, 23, 
24]. It is rational to postulate that HMGB1 can mediate 
cerebral inflammation and play a putative role in SAH-
induced delayed vasoconstriction.
4′-O-β-d-glucosyl-5-O-methylvisamminol (4OGOMV) 
is one of the four active components extracted from 
Saposhnikovia divaricata, which has been widely used in 
the treatment of headache, generalized aches and pains, 
inflammation and cancer in the Orient for centuries [25–
29]. 4OGOMV has been reported to be able to suppress 
histone H3 phosphorylation and make it able to abrogate 
the mitotic cell cycle progression and immediate pro-
inflammatory gene expression in the HeLa S-3 cell cul-
ture [30]. Increasing evidence demonstrates that histone 
phosphorylation at Ser10 plays a critic role in cellular 
mitotic progression and induces immediate pro-inflam-
matory genes during the interphase [31]. Like other 
histone deacetylase inhibitors, via targeting on the regu-
lation of histone proteins and the regulation of α-tubulin 
acetylation, recent studies on histone deacetylase were 
focused on the pathogenesis of sporadic amyotrophic lat-
eral sclerosis, Alzheimer’s disease and Parkinson’s disease 
[4, 32].
Given the promising result of 4OGOMV on the block 
of cellular mitosis and its various effects of pro-inflam-
matory cytokines stimulation on endothelial dysfunction, 
the rat SAH model was used to test the hypothesis that 
4OGOMV, a natural histone deacetylase inhibitor, atten-





has been characterized as a naturally occurring and 
potent histone H3 phosphorylation inhibitor, and was 
bought from Baoji Plant Bio-Engineering Co.,Ltd., 
Shaanxi 710000-710090 PRC. Monoclonal anti-rat IL1-
β, IL-6, IL-8 and MCP-1 antibody were obtained from 
Abcam (Cambridge, MA 02139, USA), BD Transduc-
tion Lab (BD Biosciences, San Jose, CA 95060, USA), 
Upstate Biotech (Lake placid, NY 12946, USA), and 
Santa Cruz Biotech (Santa Cruz Biotechnology, Inc. 
Santa Cruz, CA 95060, USA). Rabbit anti-rat HMBG1 
antibody was purchased from Biochiefdom inter-
national Co., Ltd, Taipei 11659, Taiwan distributing 
Abchem biochemicals, Cambridge, MA 02139, USA 
CNM protein extraction kits were from Biochain (Hay-
ward, CA 94545, USA). 4OGOMV was prepared by Ms. 
Wu SC (Kaohsiung Medical University Hospital, Kaoh-
siung 807. Taiwan, ROC). Dimethyl sulfoxide (DMSO) 
at a concentration of 10  mM was used as a solvent as 
well as a vehicle.
Induction of double hemorrhage SAH
Fifty-four male Sprague–Dawley rats (260–320 g; bought 
from BioLasco Taiwan Co., Ltd., Taipei 115, Taiwan. 
authorized by Charles River Lab), were enclosed in this 
study. All the protocols were approved and supervised by 
the University of Kaohsiung Medicine Animal Research 
Committee and were compliant with the Declaration of 
Helsinki (1964). The rats received anesthesia by an intra-
peritoneal injection of 7  mg/kg Zoletil 50 (VIRBAC, 
L.I.D., Carros 06516, France). 0.3 ml fresh arterial blood 
was withdrawn and injected into the cisterna magna via 
a stereotactic apparatus (Stoelting, Wood Dale, IL 60191, 
USA) [33, 34]. 0.1  ml Cerebrospinal fluid (CSF) was 
drawn by No30 Terumo needle to make sure the tip of the 
needle had been into subarachnoid space. Animals were 
placed in ventral recumbent position for 20 min to allow 
clot formation. After monitoring for respiratory distress 
and giving mechanical ventilation if needed, the animals 
were returned to the vivarium when fully awake. A habi-
tat with a 12 h light–dark cycle was offered with access 
to food and water ad labium. 48 h after 1st SAH, the ani-
mals received secondary injection of SAH to maintain 
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the tendency of vasoconstriction. Thereafter, the animals 
received perfusion–fixation 72 h after 2nd SAH.
General design of experimental groups
The animals were randomly subdivided into the follow-
ing groups (N = 9 rats): (1) sham operated (no SAH); (2) 
SAH-only; (3) SAH-plus vehicle; (4) 4OGOMV (100 μg/
kg/day) treatment in SAH rats; (5) SAH rats received 
200  μg/kg/day 4OGOMV treatment; and (6) treatment 
with 400 μg/kg 4OGOMV in SAH rats. The dosage was 
adjusted to be devoid of hepatic-renal toxicity based on 
the pilot rabbit artery ring study. The administration 
was initialized at 1 h after induction of SAH by using an 
osmotic mini-pump (Alzet corp, Palo Alto, CA 94301, 
US) to offer a constant serum level. Cortical tissue sam-
ples were obtained by inserting a 24-gauge needle 5 mm 
into the skull bone (N = 5) through a burr hole craniec-
tomy (2  mm apart from the bregma) under a negative 
pressure.
Perfusion–fixation
By 72 h after 2nd SAH, the animals were re-anesthetized 
by administration of 7 mg/kg Zoletil 50. Perfusion–fixa-
tion was performed to open the chest, catheterize with 
a NO16 needle into the left ventricle as well as the 
clamped descending aorta, and incise the right atrium. 
100 ml of 0.01 M phosphate buffer (pH 7.4) at a pressure 
of 80 mmHg was dripped, followed by 120 ml 2 % para-
formaldehyde in the PBS solution at 36 °C. The brain was 
extracted and immersed in a fixative at 4  °C overnight. 
Visual inspection observed blood clots formed over the 
basilar artery (BA) in all SAH animals.
Hemodynamic measurements
Heart rate, blood pressure, and rectal temperature were 
monitored in the duration of the administration of 
4OGOMV as well as at intervals of 12  h by a tail-cuff 
method (SC1000 Single Channel System, Hatteras Instru-
ments, NC 27518, US) and rectal thermometer (BIO-
BRET-2-ISO. FL 33780, US). The femoral artery was 
catheterized to obtain blood samples to determine arte-
rial blood gas, Na+, K+, glutamate oxaloacetate transami-
nase (GOT), glutamate pyruvate transaminase (GPT), 
blood urea nitrogen (BUN) and creatinine levels.
Neurological assessment
Two neurological tests were enclosed in this study. A 
modified limb-placing test (MLPT) [35] was performed 
before and at a 48 h interval after the animals were sub-
jected to SAH. The behavioral assessment was composed 
of forelimb and hindlimb ambulation and placing/step-
ping reflex examinations performed before and after 
animals were subjected to SAH. A motor deficit index 
(MDI) was calculated for each rat at an interval of 24 h. 
The final index was the sum of the scores (walking with 
lower extremities and placing/stepping reflex). Animals 
with MDI score more than three were considered as par-
aplegia, whereas MDI score less than three was consid-
ered as neurological deficit. Another modified Voetsch 
neuro-score was performed, which is composed of the 
evaluation of head movement, confrontation, reflex stim-
ulated by ear pinch, proprioception and four limbs move-
ment. The summation of neuroscore ranged from 30 to 0, 
which stood for normal performance to comatose status 
and paraplegia [36]. The neuroscore was represented as 
the percentage difference of the mean performance from 
sham-operated groups.
Basilar artery morphologic studies
Five BA cross-sections of each animal (the middle 
third) were analyzed by two investigators blinded to the 
experiment set. The basilar arteries were frozen and cut 
into 25-μm-thick sections with the assistance of ultra-
microtome E (Leica EM UC7, Union Optical and Instru-
ments and Nanotechnology. New Taipei City, 22101 
Taiwan.) The cross-sectional area of BA was automati-
cally evaluated via a computer-assisted morphometer 
(Image-1/Metamorph Imaging System; Universal Imag-
ing Corp. Sunnyvale, CA 94089, USA). The mean aver-
age of five cross-sections of a given animal was collected 
for every animal. Group data were expressed as the 
mean ± standard deviation.
Quantification of mRNA expression of IL‑1β, IL‑6, IL‑8, 
and MCP‑1
The CSF cytokines mRNA was examined via the ABI 
PRISM® 7900 System (Applied Biosystems, Foster 
City, CA 94404, USA). According to the manufactur-
er’s instructions, the mRNAs for IL-1β, IL-6, IL-8, and 
MCP-1 expression were determined, while 18S was 
used as a standard control based on its stability. Primer 
sequences were employed for IL-1β: (242  bp: forward 
5′-GCTCATCTGGGATCCTCTCC-3′ and reverse 
5′-CCTGCCTGAAGCTCTTGTTG-3′); IL-6: (91 bp: for-
ward 5′-GACAACTTTGGCATTGTGG-3′ and reverse 
5′-ATGCAGGGATGATGTTCTG-3′); IL-8: (229  bp: for-
ward 5′-TCTGCAGCTCTGTGTGAAGG-3′ and reverse 
5′-ACTTCTCCACAACCCTCTGC-3′) and MCP-1: 
(457  bp: forward 5′-CTCTTCCTCCACCACTATGC-3′ 
and reverse 5′-CTCTGTCATACTGGTCACTTC-3′). 
Each sample was launched into a TaqM Each sample was 
launched into a TaqMan® Human Cytokine Card that 
enclosed probes and primers for specific targets. This pro-
cedure was performed via an affixed filling reservoir and a 
vacuum-loading process via the ABI PRISM® Card Filling 
Station. Final data were expressed as a relative fold from 
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the baseline. Comparative mRNA expression was set by 
the Livak and Schmittgen ∆CT method [38]. The results 
were analyzed if a fivefold increase in the mRNA levels 
compared with the baseline to allow for data consistency.
HMGB1 protein analyzed by western blotting
The cortical homogenates (20 μg) were stirred with LDS 
sample buffer (contains 40 % glycerol, 4 % lithium dode-
cyl sulfate (LDS), 0.8  M triethanolamine-Cl pH 7.6, 4  % 
Ficoll®-400, 0.025  % phenol red, 0.025  % Coomassie 
G250, 2  mM EDTA disodium, NuPAGE® LDS Sample 
Buffer (4×) NP0007; Invitrogen, Carlsbad, CA 92008, 
USA). Samples were loaded for 8 % sodium dodecyl sul-
fate–polyacrylamide gel electrophoresis (SDS-PAGE) and 
then separated after centrifuging at 12,000 rpm for 10 min 
twice. The specimen was then mounted onto a polyvi-
nylidene difluoride membrane and incubated in blocking 
buffer (5 % non-fat dry milk in Tris-buffered saline with 
0.2  % Tween 20) at room temperature. Rabbit anti-rat 
HMGB1 monoclonal antibody (1:50,000; Biochiefdom 
International Co., Ltd Wenshen District, Taipei 11659, 
Taiwan. distributing Abcam biochemicals, Cambridge, 
MA 02139, USA) was used, while β-Actin (monoclonal 
anti-β-actin, dilution 1:40,000; Sigma-Aldrich, Taipei 116, 
Taiwan) was used as a loading control. A secondary anti-
body was conjugated with horseradish peroxidase (HRP) 
in TBS-t at room temperature for 1 h. The immunoblots 
were developed via a GS-700 digital scan and Molecular 
Analyst® (a GS-700 digital densitometer, GMI, Ramsey, 
MN 55303, USA). Relative optical densities were obtained 
by comparison between the measured values and the 
mean values from the vehicle plus SAH groups.
Detection of HMGB1 mRNA by rt‑PCR
The activated HMGB1 mRNA levels in the cortical 
homogenates were determined by TriPure RT-PCR Rea-
gent (Roche Diagnostics Corp. IN 46256, USA). As fol-
lowing the manufacturer’s instructions, the PCR primer 
sequences were designed according to the HMGB1 and 
glyceraldehyde-3-phosphate dehydrogenase gene sequences 
in GenBank. HMGB1: 285  bp; upstream: 5′-AGTT 
CAAGGACCCCAATG-3′; downstream: 5′-TGCTC 
TTCTCAGCCTTGACCA-3′. GAPDH: 347  bp; upstream: 
5′-GGAGCCAAAAGGGTCATC-3′; downstream: 5′-CCA 
GTGAGTTTCCCGTTC-3′. Through incubation with 
Avian Myeloblastosis Virus Reverse Transcriptase (AMV 
RT) (Promega, WI 53718, USA), the HMGB1 and GAPDH 
cDNA were amplified. Swirled with 1 µl ethidium bromide, 
the amplified cDNA fragments were detected via agarose 
gel electrophoresis [37]. A comet assay method was applied 
to examine the intensity of the gene bands. GAPDH mRNA 
was kept as a housekeeping gene owing to its stability. The 
tissue of five animals was collected for rt-PCR, and a mean 
average of three measurements for each animal was per-
formed to obtain a value.
Evaluation of cortical cleaved caspase ‑3 and ‑9a mRNA 
by rt‑PCR
The levels of cleaved caspase-3 and caspase-9a mRNA in the 
cortical homogenates were determined by TriPure RT-PCR 
Reagent (Roche Diagnostics Corp. IN 46256, USA). Accord-
ing to the supplier’s instructions, the primer sequences were 
designed according to the cleaved caspase-3, and -9a and 
GAPDH gene sequences as stated in GenBank. Cleaved 
caspase-3 primer is as:393  bp; forward: 5′-GGTATTGA 
GACAGACAGTGG-3′; reverse: 5′-CATGGGATCTGTT 
TCTTTGC-3′; caspase-9a primer: 889 bp; forward: 5′-GCT 
CTTCCTTTGTTCATCTCC-3′; reverse: 5′-CATCTGGC 
TCGGGGTTACTGC-3′ and GAPDH primer: 347  bp; 
forward: 5′-GGAGCCAAAAGGGTCATC-3′; reverse: 
5′-CCAGTGAGTTTCCCGTTC-3′. After incubation with 
Avian Myeloblastosis Virus Reverse Transcriptase (AMV 
RT) (Promega, WI 53711, USA), the cleaved caspase -3, -9a 
and GAPDH cDNA fragments were amplified and detected 
via agarose gel electrophoresis mixed with 1 µL of ethidium 
bromide. The intensity of the genes was measured via a 
comet assay method. GAPDH mRNA was used as a stand-
ard gene. The tissue samples of every five animals were used 
for rt-PCR and three measurements for each animal speci-
men performed by an investigator blind to the experiment 
set. Cleaved caspase-9a represented the majority of catalyzed 
pro-caspase-9.
Immuno‑staining with polyclonal anti‑rat NeuN, GFAP, 
BrdU and MCP‑1 antibody
MCP-1 recruits monocytes, memory T cells, and den-
dritic cells were detected using a video-assisted micro-
scope (×400). Briefly, isolated rat basilar arteries were 
perfused and fixed with 4  % paraformaldehyde. Coro-
nal sections of the basilar arteries were stored overnight 
on slides at −80  °C. Rabbit monoclonal anti-rat MCP-1 
antibody was used at a dilation of 1:40, and immu-
nostaining was performed for 40  min at 25  °C followed 
by drying overnight as described in the mouse mono-
clonal alkaline phosphatase anti-alkaline phosphatase 
(APAAP) technique [37]. The cerebral slice was frozen 
and cut into 30  μm-thick sections with the assistance 
of ultra-microtome E (Leica EM UC7, Union Optical 
and Instruments and Nanotechnology. New Taipei City 
22101, Taiwan) Two temporal gyrus cross-sections of 
each animal were analyzed by two investigators blinded 
to the experiment set. A rabbit polyclonal BrdU(1:400), 
NeuN(1:100) and GFAP(1:500) antibody recruited neu-
ral-specific RNA splicing was performed for 40  min at 
25 °C followed by drying overnight and detected by using 
a video-assisted microscope (×200).
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Statistical analysis
Data were expressed as the mean ±  standard deviation. 
For comparison among groups, all statistical analyses 
were performed using SPSS 19.0 software (SPSS Inc., 
Chicago, IL 60614, USA). Difference was considered sig-
nificant at a probability value less than 0.01.
Results
General observation
Throughout the study, there was no significant differ-
ence observed in the recorded physiological parameters, 
including GOT, GPT, BUN, creatinine, pH, blood pres-
sure and arterial blood gas analysis among the experi-
mental groups. This authenticated that 4OGOMV 
administration in the selected dosage was devoid of 
hepatic and renal toxicity.
Tissue morphometry and MCP‑1 immunostaining
The internal elastic lamina (IEL) in the BAs of SAH 
and SAH+vehicle groups showed substantial corru-
gation when compared with that obtained from the 
controls (Fig.  1, upper panel). IEL disruption was less 
prominent in the 200 and 400  μg/kg/day 4OGOMV 
treatment SAH groups. The cross-sectional areas of 
BAs in the SAH and SAH+vehicle groups were sig-
nificantly reduced when compared with the control 
group (0.138  ±  0.028, and 0.135  ±  0.046). 400  μg/kg 
4OGOMV attenuated SAH-induced vasoconstriction 
(Fig.  1, lower panel, P  <  0.01). Peri-vascular MCP-
1(+) cell level was significantly reduced in the 400ug/
kg/day 4OGOMV treatment and the healthy controls 
when compared with the SAH groups (p < 0.01, Fig. 2). 
Besides, the smaller branch of basilar artery was also 
dilated under the 400  μg/kg 4OGOMV treatment 
(Fig. 1, Upper panel).
Neurological deficit
MLPT score was obtained to examine the motor-sen-
sory incorporation of the forelimb and hindlimb and 
placing/stepping reflex as a reflective response to tac-
tile and proprioceptive stimuli. The sum from these 
two tests is considered as motor deficit index (MDI). 
The mean MDI in the SAH and SAH+vehicle groups 
were 2.65  ±  0.38 and 2.42  ±  0.48, compared with 
Fig. 1 Comparison of lumen cross‑sectional capacities of the basilar artery (bottom panel). Top panel represents micrographs of the BAs obtained 
from the healthy controls (a), the SAH‑only rats (b), the vehicle‑treated SAH rats (c), SAH rats receiving 100 μg/kg/day 4OGOMV treatment (d), 
SAH rats receiving 200 μg/kg/day (e), and 400 μg/kg/day 4OGOMV treatment (f). Standard bar = 200 μm. **P < 0.01: compared with the SAH and 
sham‑operated group. #P > 0.01: comparison between the SAH group and the controls. #, ##P > 0.01, *P < 0.01: 4OGOMV + SAH groups compared 
with the SAH group. Data are mean ± SD (n = 9/group)
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the healthy controls. Treatment with 4OGOMV (at 
400 μg/kg) significantly improved the MDI in the SAH 
groups (Table  1). Likewise, MDI ≥  3 was substantially 
decreased in the 4OGOMV treatment SAH groups 
when compared with the SAH animals. The percentage 
difference of modified Voetsch neuro-scores was signifi-
cantly induced in the 400  μg/kg/day 4OGOMV+SAH 
group and the healthy controls, when compared with 
the SAH groups (Table 2).
mRNA expression of IL‑1β, IL‑6, IL‑8, and MCP‑1
Following the induction of SAH, the CSF IL-1β, IL-6, 
IL-8, and TNF-α levels were found to increase 1000- and 
3000-fold at 24 and 72 h, when compared with the sham-
operated group. Administration of 4OGOMV reduced 
cytokine levels by 8, 45, 52 and 15 % for IL-1β, IL-6, IL-8, 
and MCP-1 relative to SAH groups at 48 h after 1st SAH 
(Fig. 3, left column). Levels of IL-1β and MCP-1 were sig-
nificantly reduced in the 400 μg/kg/day 4OGOMV treat-
ment SAH group. Incidentally, treatment with 4OGOMV 
failed to reduce IL-8 level to statistical difference from 
the rats subject to SAH (Fig. 3, p > 0.01).
HMGB1 protein expression
HMGB1 were demonstrated to play a critical role in 
the onset of delayed and systemic inflammation. The 
expression of HMGB1 protein was not significantly dif-
ferent among the experimental groups at 48  h after the 
induction of SAH (Fig. 4, left column, p > 0.01). In this 
study, 4OGOMV (at 200 and 400  μg/kg/day) reduced 
Fig. 2 Immuno‑staining of MCP‑1 positive leukocyte transmigrated into the perivascular adventitia. Top panel represents micrographs of the BAs 
obtained from the Sham‑operated (a), the SAH‑only rats (b), the SAH rats receiving 100 μg/kg/day 4OGOMV treatment (c), SAH rats receiving 
200 μg/kg/day (d), and 400 μg/kg/day 4OGOMV treatment (e) MCP(+) cells (arrow head), counted under the assistance of high power microscope, 
revealed brown color and the adventitia tissue was blue in H and E staining. Standard bar = 25 μm. *P < 0.01: compared with the SAH and sham‑
operated group. #, ##: P > 0.01, *P < 0.01: 4OGOMV + SAH groups compared with the SAH group. Data are mean ± SD (n = 9/group)
Table 1 Modified limb-placing test (MLPT)
Results are expressed as the mean ± SD, n = 9; *p < 0.01 vs. SAH condition by 
Mann–Whitney U test
Group treatment Ambulation Placing/stepping 
reflex
MDI
Sham‑operated 0 0 0
SAH 1.28 ± 0.17 1.50 ± 0.13 2.78 ± 0.30
SAH+vehicle 1.28 ± 0.11 1.58 ± 0.21 2.86 ± 0.32
SAH+4OGOMV
100 μg/kg/day 0.91 ± 0. 60 1.54 ± 0.25 2.45 ± 0.85
200 μg/kg/day 0. 82 ± 0.25 0.83 ± 0.43* 1.65 ± 0.68
400 μg/kg/day 0.56 ± 0.22* 0.65 ± 0.20* 1.21 ± 0.42*
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the expression of HMGB1 protein at 72 h after 2nd SAH, 
when compared with the SAH group (Fig.  4, right col-
umn, p < 0.01).
The activation of HMGB1 mRNA
To observe the neuronal inflammation subsequent to 
SAH, HMGB1 mRNA was examined. The activated 
HMGB1 mRNA was increased in the SAH groups when 
compared with the sham-operated groups (p  <  0.01). 
400  μg/kg/day 4OGOMV tended to decrease HMGB1 
mRNA in the 48 h SAH rats (Fig. 5, left column, p > 0.05). 
By 72  h post 2nd SAH, 4OGOMV dose-dependently 
reduced HMGB1 mRNA when compared with the SAH 
groups (Fig. 5, right column, p < 0.01).
Results of cleaved caspase‑3 and ‑9a mRNA expression
The cortical level of cleaved caspase-3 and -9a was sig-
nificantly increased in the SAH group, compared with 
the 4OGOMV treatment+SAH groups and the healthy 
controls. (Fig.  6, P  <  0.01) Treatment with 400  μg/kg/
day 4OGOMV reduced activated caspase-3 and caspase-
9a to a significant level when compared with that in the 
SAH rats, (Fig. 6) which corresponds to the result of neu-
robehavior examination.
NeuN, BrdU, GFAP immunostaining
NeuN(+) neurons were detected associated with vacuo-
lated nuclear in the cortex in the SAH groups, which was 
absent in the 4OGOMV treatment and sham-operated 
groups. (Fig. 7, upper panel) Likewise, the GFAP(+) glia 
was observed increased in the SAH groups. 4OGOMV 
significantly reduced cerebral activated GFAP glia, when 
compared with SAH group. (Figure 7, lower panel). The 
Table 2 Modified Voetsch neuroscores












Sham‑operated 12 ± 0 12 ± 0 6 ± 0 30 ± 0
SAH 5.2 ± 2.2 4.6 ± 1.8 3.1 ± 0.5 12.9 ± 4.5
SAH+vehicle 6.2 ± 2.6 5.5 ± 2.1 2.7 ± 0.8 14.4 ± 7.5
SAH+4OGOMV
100 μg/kg/day 6.9 ± 1. 6 6.5 ± 2.5 3.7 ± 0.5 17.1 ± 4.6
200 μg/kg/day 8.2 ± 2.4 9.6 ± 1.3 4.0 ± 1.0 21.7 ± 4.7
400 μg/kg/day 9.6 ± 2.5 10.2 ± 3.2* 4.3 ± 1.5 24.1 ± 7.2*
Fig. 3 Bar graph depicting 4OGOMV on the time‑course change of pro‑inflammatory cytokines after the induction of double shot SAH. Data are 
depicted for IL‑1β, IL‑6, IL‑8, MCP‑1 at 48 h after 1st SAH and 72 h post 2nd SAH. Data in the figure are presented as mean ± SD (n = 9). *, **P < 0.01, 
and #, ##, ###P > 0.01 when compared with the SAH group
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middle panel revealed the BrdU staining in the Sham-
operated, SAH and 400  μg/kg/day 4OGOMV+SAH 
group. Even the contour of cerebrum was not deformed, 
the lethal effect of SAH related brain injury was observed, 
which corresponds to the observation of cleaved caspases 
mRNA related apoptosis (Fig. 6).
Discussion
In the present study, 4OGOMV, a natural compound, has 
been shown to attenuate SAH-induced IL-1β and MCP-1 
expression at the initial stage of SAH. However, how to 
maintain the intensity of neuro-inflammation in delayed 
vasoconstriction remains unknown. HMGB1, a late-
produced immunity mediator, showed a clue to investi-
gate the mechanism of SAH-induced delayed cerebral 
ischemia. In Li et  al’s study, 4OGOMV is demonstrated 
to modulate the vasoconstriction on rabbit isolated basi-
lar artery rings evoked by KCl and 5-HT [25]. In Wang 
et al’s group, 4OGOMV was proven to be able to inhibit 
the proliferation of smooth muscle cells stimulated by 
TNF-α in a smooth muscle cell culture [27]. In the study 
of human colon cancer HT-29 cells, 4OGOMV is shown 
to inhibit the phosphorylation of histone H3 at Ser10, 
which is responsible for two important biological func-
tions: serving as a feasible epigenetic strategy to inhibit 
the mitotic cell cycle progression and transcriptional 
activation of immediate pro-inflammatory genes during 
the interphase [11, 24]. Likewise, in the observation of 
NeuN, GFAP and BrdU polyclonal immunostating, our 
result supports 4OGOMV, in a selected dose, is able to 
reduce pro-inflammatory cytokines in the early stage of 
SAH-induced vascular deformity and also attenuate SAH 
induced cerebral apoptosis.
Elevated CSF IL-1β, IL-6, IL-8, TNF-α and adhesion 
molecule levels have been observed mediated by acti-
vated glia and imposed in the pathogenesis of aneurismal 
SAH-induced vasospasm [10, 39, 40]. In Bowman et al’s 
study, a polyclonal antibody targeted against IL-6 was 
able to alleviate SAH-induced vasoconstriction in a femo-
ral artery SAH model [41]. A cumulative result indicated 
that the upregulation of pro-inflammatory cytokines is 
antecedent to radiographic vasospasm (peak at 4th to 
14th days after aneurysmal SAH in human subjects) [1, 
40, 42], and attenuation of cytokines tends to minimize 
Fig. 4 The time‑course expression for High‑mobility group protein B1 (HMGB1) in the SAH rats (Western blot). a SAH; b SAH + vehicle; c 100 μg/
kg/day 4OGOMV +SAH; d 200 μg/kg/day 4OGOMV +SAH, and e 400 μg/kg/day 4OGOMV in SAH rats. 4OGOMV dose‑dependently attenuated 
HMGB1 protein expression at 72 h. *, **P < 0.01, experimental animals compared with the SAH group. #, ##P > 0.01, compared with the animals 
subject to SAH
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vascular constriction and reduced cerebral infarct in ani-
mals. In this study, IL-1β, and MCP-1 (at 48 h after 1st 
SAH)) levels were suppressed by the administration of 
4OGOMV (at 200 and 400 μg/kg), while IL-6 level was 
reduced at 400 μg/kg 4OGOMV treatment group at 72 h 
after 2nd SAH.
Monocyte chemoattractant protein-1 (MCP-1), also 
known as chemokine ligand 2(CCL2), is one of the major 
chemokines that regulate monocytes/macrophages 
migration and infiltration [11, 12, 43, 44]. Both CCL2 and 
its receptor CCR2 have been demonstrated to be induced 
and involved in various diseases such as idiopathic 
inflammatory myopathy, cytomegalovirus encephali-
tis, atherosclerosis, Alzheimer’s disease, traumatic brain 
injury and rheumatic arthropathy [15, 22, 23]. Monocyte 
migration from the blood flow to the vascular endothe-
lium is needed for routine surveillance of tissues in 
response to inflammation. Besides, CCL2 is reported to 
induce amylin expression through ERK1/ERK2/JNK-AP1 
and NF-κB-related signaling pathways. Amylin upregula-
tion by CCL2 contributes to the elevation of the plasma 
amylin and insulin resistance in obesity [3]. In this study, 
MCP-1 positive cells were observed reduced in the media 
and adventitia of basilar artery in the 200 and 400 μg/kg 
4OGOMV treatment SAH group, when compared with 
the SAH groups.
High-mobility group box 1 (HMGB1), a trigger of 
inflammation, tissue repair, with a characteristic of 
attracting inflammatory cells, recruiting stem cells and 
promoting their proliferation, is released by activated 
monocytes, macrophages, neutrophils, platelets and 
microglia [8, 17]. It is demonstrated to mediate the 
immediate and delayed inflammatory responses of vas-
cular endothelial cells. As a late mediator, HMGB1 par-
ticipated in the pathogenesis of chronic and prefunded 
inflammation after the early immunity response has 
resolved [13]. Through bond to transmembrane recep-
tors, like advanced glycation end products (RAGE), 
toll-like receptor (TLR)-2, TLR-4, activated nuclear 
factor-κB (NF-κB), extracellular regulated kinase (ERK) 
1 and ERK 2 [16]. Moreover, HMGB1 also induced the 
expression of adhesion molecules from the activated 
platelets and microglia to up-regulate the recruit-
ment of inflammation. Qiu et  al. stated inhibition of 
HMGB1 expression is able to reduce focal cerebral 
ischemia insult by inhibiting the HMGB1/RAGE axis 
Fig. 5 HMGB1 mRNA expression on 48 h after 1st SAH and 72 h after 2nd SAH, respectively (rt‑PCR). All groups are identical to those shown in the 
legends of Fig. 4. #, ##, ###P > 0.01; *, **P < 0.01: represent 4OGOMV treatment significantly attenuated HMGB1 mRNA transcription at a late stage of 
SAH, when compared with the SAH groups
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[45]. In this study, 4OGOMV (at 200 and 400 μg/kg) is 
able to restrict HMGB1 mRNA transcription and pro-
tein expression-induced delayed neuro-inflammation 
by 72  h after the induction of 2nd SAH, which corre-
sponds to the observation of reduced IL-1β, IL-6 and 
MCP-1 level in the 4OGOMV treatment groups. More-
over, the preri-vascular MCP(+) cells were significantly 
decreased dose-dependently in the 4OGOMV treat-
ment SAH rats.
In summary, the results of this study show that admin-
istration of 4OGOMV, at a therapeutic dosage, is effica-
cious in the prevention of experimental vasoconstriction 
and improvement of neuro-behavior function. There are 
few reports about the bio-function of 4OGOMV, such as 
a novel epigenetic suppressor of histone H3 phosphoryla-
tion in a colon cancer cell lines, vasodilation effect on a 
rabbit isolated basilar artery rings, and suppression of 
smooth muscle cell hyperplasia induced by TNF-α [24, 
26]. This is the first study indwelled in the immunosup-
pressive effect of 4OGOMV on SAH-induced vasos-
pasm. Besides, 4OGOMV, by reducing HMGB1 mRNA 
activation, exerts a dual effect on microglia-related T cell 
transmigration and IL-6-related delayed inflammatory 
cascade.
Likewise, when considering the neuroprotective effect 
of 4OGOMV on the SAH rats, activated caspases-3 and 
-9a, which correspond to mitochodria related cellular 
apoptosis, were significantly reduced in the 400  μg/kg/
day 4OGOMV treatment groups, when compared with 
the SAH rats. In mammals, there are three major path-
ways observed in the mitochondria related apoptosis: 
(1) the extrinsic receptor-related pathway; (2) the intrin-
sic pathway and (3) the cytotoxic lymphocyte-initiated 
granzyme B pathway [46, 48]. Shi el al has identified 14 
caspases and subdivided them into one initiator group, 
such as caspase-8 and -9, one downstream effecter group, 
like caspase-3, -6, and -7, and another pro-inflamma-
tory group, enrolled caspases-1, -4, -5, -11, -12, and -13 
[47]. Caspase-3 is believed to be the major effecter cas-
pase in neuronal apoptosis. Caspase-3 played a critical 
role in determining profound cerebral hyperplasia and 
deployment disorganization was observed in a study of 
caspase-3 knockout mice [46]. By now, the distinct roles 
of each caspase are still undefined. Besides, caspases 
act on upstream intrinsic apoptosis and downstream 
of cytochrome c release [47]. In this study, 4OGOMV 
was observed able to reduce the initiator caspase-9a 
(at 400  μg/kg/day) and decrease effector Ccspase-3 (at 
Fig. 6 Level of activated caspase‑3 and ‑9a in the SAH rats received 4OGOMV treatment (rt‑PCR). Top panel: Groups were arranged as stated in 
Fig. 5. Bar graph reveled 400 μg/kg/day 4OGOMV treatment significantly decreased both cleaved caspase‑3 and caspase‑9a level in the SAH rats 
(p < 0.01). Data are showed as mean ± SD. (*P < 0.01, and #, ##P > 0.01: comparison among the 100/200/400 μg/kg/day 4OGOMV treatment and 
SAH groups
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400  μg/kg/day). It is believed 4OGOMV, at a selected 
dose, is devoid of hepatic and systemic toxicity and has a 
neuroprotective effect by blocking both initiator caspase-
9a and effector caspase-3 activation as other HDAI does 
[49].
Conclusions
The acuminated results arouse interest to consider the 
pathogenesis of SAH-induced acute and delayed neuro-
inflammation and its effect dictates on the patient’s out-
come. The breakout of T-cell immigration accompanying 
SAH is a critical and complicated pathway underlying the 
development and maintenance of delayed neurologic def-
icits. Our study shows that administration of 4OGOMV 
may diminish SAH-induced early pro-inflammation 
and subsequent HMGB1 stimulation in a rodent model 
of SAH. This study suggests that 4OGOMV, a natural 
occurring potent immunosuppressant in a selected dose, 
could prove clinically useful in preventing and treating 
SAH-induced vasospasm and early brain injury.
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